Image-guided convection-enhanced delivery platform in the treatment of neurological diseases - PubMed (original) (raw)

Review

Image-guided convection-enhanced delivery platform in the treatment of neurological diseases

Massimo S Fiandaca et al. Neurotherapeutics. 2008 Jan.

Abstract

Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials for gene therapy in Parkinson's disease (PD). Benefits of this intracranial drug-transfer technology include a more efficient delivery of large volumes of therapeutic agent to the target region when compared with more standard delivery approaches (i.e., biopolymers, local infusion). In this article, we describe specific technical modifications we have made to the CED process to make it more effective. For example, we developed a reflux-resistant infusion cannula that allows increased infusion rates to be used. We also describe our efforts to visualize the CED process in vivo, using liposomal nanotechnology and real-time intraoperative MRI. In addition to carrying the MRI contrast agent, nanoliposomes also provide a standardized delivery vehicle for the convection of drugs to a specific brain-tissue volume. This technology provides an added level of assurance via visual confirmation of CED, allowing intraoperative alterations to the infusion if there is reflux or aberrant delivery. We propose that these specific modifications to the CED technology will improve efficacy by documenting and standardizing the treatment-volume delivery. Furthermore, we believe that this image-guided CED platform can be used in other translational neuroscience efforts, with eventual clinical application beyond neuro-oncology and PD.

PubMed Disclaimer

Similar articles

• Image-guided convection-enhanced delivery into agarose gel models of the brain.
  Sillay KA, McClatchy SG, Shepherd BA, Venable GT, Fuehrer TS. Sillay KA, et al. J Vis Exp. 2014 May 14;(87):51466. doi: 10.3791/51466. J Vis Exp. 2014. PMID: 24894268 Free PMC article.
• Anatomic compression caused by high-volume convection-enhanced delivery to the brain.
  Valles F, Fiandaca MS, Bringas J, Dickinson P, LeCouteur R, Higgins R, Berger M, Forsayeth J, Bankiewicz KS. Valles F, et al. Neurosurgery. 2009 Sep;65(3):579-85; discussion 585-6. doi: 10.1227/01.NEU.0000350229.77462.2F. Neurosurgery. 2009. PMID: 19687704 Free PMC article.
• Infusion-line pressure as a real-time monitor of convection-enhanced delivery in pre-clinical models.
  Lam MF, Foo SW, Thomas MG, Lind CR. Lam MF, et al. J Neurosci Methods. 2014 Jan 15;221:127-31. doi: 10.1016/j.jneumeth.2013.09.019. Epub 2013 Oct 8. J Neurosci Methods. 2014. PMID: 24120968
• Convection-enhanced delivery of targeted toxins for malignant glioma.
  Hall WA, Sherr GT. Hall WA, et al. Expert Opin Drug Deliv. 2006 May;3(3):371-7. doi: 10.1517/17425247.3.3.371. Expert Opin Drug Deliv. 2006. PMID: 16640497 Review.
• Neurosurgical convection-enhanced delivery of treatments for Parkinson's disease.
  Lam MF, Thomas MG, Lind CR. Lam MF, et al. J Clin Neurosci. 2011 Sep;18(9):1163-7. doi: 10.1016/j.jocn.2011.01.012. Epub 2011 Jul 13. J Clin Neurosci. 2011. PMID: 21745745 Review.

Cited by

• Immunologic privilege in the central nervous system and the blood-brain barrier.
  Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, Engelhardt B, Hallenbeck JM, Lonser RR, Ohlfest JR, Prat A, Scarpa M, Smeyne RJ, Drewes LR, Neuwelt EA. Muldoon LL, et al. J Cereb Blood Flow Metab. 2013 Jan;33(1):13-21. doi: 10.1038/jcbfm.2012.153. Epub 2012 Oct 17. J Cereb Blood Flow Metab. 2013. PMID: 23072749 Free PMC article. Review.
• Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors.
  Mehkri Y, Woodford S, Pierre K, Dagra A, Hernandez J, Reza Hosseini Siyanaki M, Azab M, Lucke-Wold B. Mehkri Y, et al. Curr Oncol. 2022 Nov 17;29(11):8846-8861. doi: 10.3390/curroncol29110696. Curr Oncol. 2022. PMID: 36421349 Free PMC article. Review.
• Advances in image-guided intratumoral drug delivery techniques.
  Solorio L, Patel RB, Wu H, Krupka T, Exner AA. Solorio L, et al. Ther Deliv. 2010 Aug;1(2):307-22. doi: 10.4155/tde.10.20. Ther Deliv. 2010. PMID: 22816134 Free PMC article. Review.
• Convection-enhanced delivery for the treatment of brain tumors.
  Debinski W, Tatter SB. Debinski W, et al. Expert Rev Neurother. 2009 Oct;9(10):1519-27. doi: 10.1586/ern.09.99. Expert Rev Neurother. 2009. PMID: 19831841 Free PMC article. Review.
• Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.
  San Sebastian W, Richardson RM, Kells AP, Lamarre C, Bringas J, Pivirotto P, Salegio EA, Dearmond SJ, Forsayeth J, Bankiewicz KS. San Sebastian W, et al. Hum Gene Ther. 2012 Feb;23(2):210-7. doi: 10.1089/hum.2011.162. Epub 2012 Jan 26. Hum Gene Ther. 2012. PMID: 22017504 Free PMC article.

References

1. 1. Oldendorf WH. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med. 1974;147:813–815. - PubMed
2. 1. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery. 2004;54:131–140. doi: 10.1227/01.NEU.0000097715.11966.8E. - DOI - PubMed
3. 1. Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet. 2006;45:871–903. doi: 10.2165/00003088-200645090-00002. - DOI - PubMed
4. 1. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083–1099. doi: 10.1097/00006123-199805000-00082. - DOI - PubMed
5. 1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126. doi: 10.1200/JCO.2005.09.131. - DOI - PubMed

Publication types

MeSH terms

Grants and funding

• R01 NS050156/NS/NINDS NIH HHS/United States
• R01 NS050156-02/NS/NINDS NIH HHS/United States
• R01 NS056107/NS/NINDS NIH HHS/United States
• R01 NS056107-02/NS/NINDS NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information